drug study ziprasidone

Drug Data Classification Mechanism of Action Indication Contraindications Side Effects Nursing Responsibilities Generic Name: Ziprasidone rade Name: Geodon Ma!imum Dose: 80 mg twice daily Minimum Dose: 10 mg/day A"ailabilit#: Capsules: 20 mg, 40, 60, 80 mg Lyophilized powde !o in"ection: 20 mg/#ial Route: $%, &' $harmacologi c: (enziso)azole dei#ati#e herapeutic: *ntipsychotic $regnanc# Categor#:C +electi#ely loc-s seotonin and dopamine eceptos in the mesocotical tact o! the C.+, theey suppessing psychotic symptoms A: 60 asoed !ollowing oal administation 100 asoed !om $% sites D: un-nown M % E: metaolized y the li#e 3 1 e)ceted unchanged in uine &alf' life: &' 5 h $%: 27 h Route (nset $%: within hs &': apid $ea) $%: 1 days &': 60 min Duration 9n-nown To treat schizophren ia To treat acute manic or mixed episodes of bipolar disorder As adjunct to lithium or valproate for maintenanc e treatment of bipolar I disorder Concuent use o! othe dugs that polong ; inte#al, histoy o! ahythmia, hypesensiti#ity to zipasidone o its components, histoy o! polonged ; inte#al, ecent acute %$, uncompensated heat !ailue Drug Interactions: antihypertensives: *dditi#e antihypetensi#e e!!ects carbamazepine: &ossily deceased lood zipasidone le#el CNS depressants: $nceased C.+ depession dopamine agonists levodopa: <eceased theapeutic e!!ects o! these dugs drugs that prolong !T interval "including #uinidine dofetilide pimozide sotalol thioridazine and sparfloxacin$: $nceased is- o! polonged ; o ;c inte#al, tosades de pointes, and sudden death %etoconazole: &ossily inceased lood zipasidone le#el *((DS all foods: $nceased zipasidone asoption CNS: neuoleptic malignant syndome, paesthesia, pesonality o speech disode, seotonin syndome, somnolence, syncope, suicidal ideation, tadi#e dys-inesia, temo C+:polonged ; o ;c inte#al, tachycadia, thomophleitis , #asodilation EEN: *nomal #ision, dy mouth, END(: <ysmenohea, hypeglycemia GI: *dominal pain, anoe)ia, G,: &iapism, uinay incontinence &EME: *ganulocytosis, leu-openia, neutopenia MS: *thalgia, ac- pain, dysathia, myalgia RES$: Cough, pulmonay emolism, uppe espiatoy tact in!ection -efore: Chec- !o docto=s ode Chec- #ital signs Con!im patient=s identity and ight dose and oute &otect zipasidone #ials !om light During: Gi#e medication at the ight oute Gi#e the ight medication at the ight dosage Gi#e %edication at the ight time >econstitute y adding 12 ml steile wate !o in"ection to #ial and sha-ing #igoously until dug is dissol#ed Gi#e only y $% oute >econstituted dug may e stoed 24 hous potected !om light o up to 5 days i! e!igeated and potected !om light *dministe $% !om cautiously to patients with impaied enal !unction After: immediate documentation a!te medication administation %onito patient closely !o anaphyla)is *ssess cadiac hythm in patients with hypo-alemia o hypomagnesemia $mmediately epot e#idence o! neuoleptic malignant syndome, a ae ut potentially !atal ad#ese eaction including hypepye) ia, muscle igidity, alteed mental status, iegula pulse, lood pessue changes, tachycadia, diaphoesis, ahythmia, myogloinuia monito patient closely !o suicidal tendencies Source: Drug Stud#

Upload: arnzz-agbulos

Post on 04-Jun-2018

217 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

8/13/2019 Drug Study Ziprasidone

http://slidepdf.com/reader/full/drug-study-ziprasidone 1/2

Drug Data Classification Mechanism of Action Indication Contraindications Side Effects Nursing Responsibilities

GenericName:Ziprasidonerade Name:Geodon

Ma!imum

Dose:80 mg twicedaily

MinimumDose:10 mg/day

A"ailabilit#:Capsules: 20mg, 40, 60, 80mgLyophilized

powde !oin"ection: 20mg/#ial

Route:$%, &'

$harmacologic:(enziso)azoledei#ati#e

herapeutic:*ntipsychotic

$regnanc#Categor#:C

+electi#ely loc-s seotoninand dopamineeceptos in themesocotical tact o! theC.+, theey suppessingpsychotic symptoms

A: 60 asoed !ollowingoal administation 100 asoed !om $% sitesD: un-nownM % E: metaolized ythe li#e 3 1 e)cetedunchanged in uine&alf' life: &' 5 h $%: 27h

Route(nset

$%: within hs

&': apid

$ea)$%: 1 days&': 60 min

Duration 9n-nown

To treatschizophreniaTo treatacute manicor mixedepisodesof bipolar

disorder Asadjunct tolithium orvalproatefor maintenance treatmentof bipolar Idisorder

Concuent use o!othe dugs thatpolong; inte#al, histoy o!ahythmia,hypesensiti#ityto zipasidone o itscomponents,

histoy o! polonged; inte#al,ecent acute %$,uncompensated heat!ailue

Drug Interactions:antihypertensives:*dditi#eantihypetensi#ee!!ectscarbamazepine:&ossily deceased

loodzipasidone le#elCNS depressants:$nceased C.+depessiondopamine agonistslevodopa: <eceasedtheapeutic e!!ects o!these dugsdrugs that prolong !Tinterval "including#uinidine dofetilide pimozide sotalol

thioridazineand sparfloxacin$:$nceased is- o! polonged ; o ;cinte#al, tosades depointes, and suddendeath%etoconazole:&ossily inceasedloodzipasidone le#el*((DSall foods: $nceasedzipasidoneasoption

CNS: neuolepticmalignantsyndome,paesthesia,pesonality ospeech disode,seotoninsyndome,

somnolence,syncope, suicidalideation, tadi#edys-inesia,temoC+:polonged ;o ;c inte#al,tachycadia,thomophleitis, #asodilationEEN: *nomal#ision, dymouth,

END(:<ysmenohea,hypeglycemiaGI: *dominalpain, anoe)ia,G,: &iapism,uinayincontinence&EME:*ganulocytosis,leu-openia,neutopeniaMS: *thalgia,

ac- pain,dysathia,myalgiaRES$: Cough,pulmonayemolism, uppeespiatoy tactin!ection

-efore:

Chec- !o docto=s ode

Chec- #ital signs

Con!im patient=s identity andight dose and oute

&otect zipasidone #ials !omlight

During:

Gi#e medication at the ightoute

Gi#e the ight medication atthe ight dosage

Gi#e %edication at the ighttime

>econstitute y adding 12 mlsteile wate !o in"ection to#ial and sha-ing #igoouslyuntil dug is dissol#ed

Gi#e only y $% oute

>econstituted dug may e

stoed 24 hous potected!om light o up to 5 days i!e!igeated and potected!om light

*dministe $% !omcautiously to patients withimpaied enal !unction

After:

immediate documentationa!te medicationadministation

%onito patient closely !oanaphyla)is

*ssess cadiac hythm inpatients with hypo-alemia ohypomagnesemia

$mmediately epot e#idenceo! neuoleptic malignantsyndome, a ae utpotentially !atal ad#eseeaction includinghypepye)ia, muscle igidity,alteed mentalstatus, iegula pulse, loodpessue changes,tachycadia, diaphoesis,

ahythmia, myogloinuia monito patient closely !o

suicidal tendencies

Source:

Drug Stud#